| Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (NCT02613403) | Merck Sharp & Dohme LLC | 2015-12-10 |
| Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination (NCT02590068) | Rockefeller University | 2015-12-01 |
| A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) (NCT02556086) | Bristol-Myers Squibb | 2015-12-01 |
| Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S. (NCT02641158) | Columbia University | 2015-12-01 |
| A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3 (NCT02551861) | Bristol-Myers Squibb | 2015-12-01 |
| Current Treatment of HCV Infection After HSCT (NCT03014986) | European Society for Blood and Marrow Transplantation | 2015-12-01 |
| Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection (NCT02591277) | Gilead Sciences | 2015-11-30 |
| Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (NCT02607800) | Gilead Sciences | 2015-11-16 |
| Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection (NCT02562742) | Gilead Sciences | 2015-11-12 |
| Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea (NCT02727933) | Bristol-Myers Squibb | 2015-11-03 |
| Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy (NCT03483818) | NHS Tayside | 2015-11-01 |
| A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat (NCT02565888) | Radboud University Medical Center | 2015-11-01 |
| Antiviral Pharmacology and Adherence in Drug Users (NCT02573376) | University of Colorado, Denver | 2015-11-01 |
| Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults (NCT03181074) | Bristol-Myers Squibb | 2015-10-21 |
| Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa (NCT02405013) | ANRS, Emerging Infectious Diseases | 2015-10-01 |
| Hepatitis C Testing in VA Community-Based Outpatient Clinics (NCT02936648) | VA Office of Research and Development | 2015-10-01 |
| Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents. (NCT02802280) | Instituto de Investigación Marqués de Valdecilla | 2015-10-01 |
| C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study (NCT02568540) | Boston Children's Hospital | 2015-10-01 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (NCT02194998) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-16 |
| Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics (NCT02596880) | Tehran University of Medical Sciences | 2015-09-01 |
| A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection (NCT02496078) | Bristol-Myers Squibb | 2015-08-01 |
| Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs (NCT02532907) | University of Colorado, Denver | 2015-08-01 |
| Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C (NCT02526641) | University of Aarhus | 2015-08-01 |
| Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD) (NCT02503735) | Massachusetts General Hospital | 2015-07-15 |
| Pilot HCV Direct Acting Antiviral Therapy and Metabolism (NCT02734173) | Ottawa Hospital Research Institute | 2015-07-01 |
| Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP) (NCT02749864) | Instituto de Investigación Marqués de Valdecilla | 2015-07-01 |
| Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (NCT02657694) | FixHepC | 2015-07-01 |
| A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 (NCT02441283) | AbbVie | 2015-06-22 |
| Way to Cure HCV Adherence (NCT02472925) | University of Pennsylvania | 2015-06-01 |
| Biomarkers of Liver Fibrosis (NCT02438917) | Icahn School of Medicine at Mount Sinai | 2015-06-01 |
| Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens (NCT02505243) | Radboud University Medical Center | 2015-06-01 |
| Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (NCT02455167) | University of Colorado, Denver | 2015-05-01 |
| Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002) (NCT02392494) | Merck Sharp & Dohme LLC | 2015-04-28 |
| Prevalence and Screening of Hepatitis C in Belgium in 2015 (NCT02393365) | Brugmann University Hospital | 2015-03-10 |
| Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C (NCT01707030) | VA Office of Research and Development | 2015-03-01 |
| Qualification of Point-of-Care Assays for Management of HCV Patients (NCT02335320) | ANRS, Emerging Infectious Diseases | 2015-03-01 |
| Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period (NCT02531269) | Bristol-Myers Squibb | 2015-03-01 |
| Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) (NCT02358044) | Merck Sharp & Dohme LLC | 2015-02-27 |
| International Validation of a Sexual Quality of Life Questionnaire Specific to HIV and Hepatitis C (PROQOL-SexLife) (NCT03468673) | University Paris 7 - Denis Diderot | 2015-02-20 |
| Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis (NCT02319031) | Bristol-Myers Squibb | 2015-02-01 |
| The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (NCT02363517) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2015-02-01 |
| eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs (NCT04047680) | National Taiwan University Hospital | 2015-02-01 |
| Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) (NCT02332720) | Merck Sharp & Dohme LLC | 2015-01-28 |
| Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) (NCT02251990) | Merck Sharp & Dohme LLC | 2015-01-28 |
| Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) (NCT02332707) | Merck Sharp & Dohme LLC | 2015-01-22 |
| Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C (NCT02528461) | University of Aarhus | 2015-01-01 |
| Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons (NCT02316184) | Butler Hospital | 2015-01-01 |
| Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood (NCT02718573) | Icahn School of Medicine at Mount Sinai | 2015-01-01 |
| Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (NCT02992457) | Tanta University | 2015-01-01 |
| Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics (NCT02304159) | Tarek I. Hassanein, M.D., FACP, FAG, AGAF | 2015-01-01 |
| HCV Treatment in a Low-threshold Clinic (NCT04063839) | University Hospital, Akershus | 2015-01-01 |
| Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003) (NCT02269059) | Merck Sharp & Dohme LLC | 2014-12-01 |
| An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (NCT02278419) | Janssen-Cilag International NV | 2014-12-01 |
| Immune Monitoring of Hepatitis C Under DAA Therapy (NCT02904603) | University of Regensburg | 2014-11-01 |
| Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) (NCT02204475) | Merck Sharp & Dohme LLC | 2014-11-01 |
| Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia (NCT02361541) | Institute of Tropical Medicine, Belgium | 2014-11-01 |
| Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034. (NCT02315638) | Tacere Therapeutics, Inc. | 2014-11-01 |
| Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) (NCT02252016) | Merck Sharp & Dohme LLC | 2014-10-22 |
| Vertical Transmission of Hepatitis C Virus (NCT02044042) | Hopital Lariboisière | 2014-10-01 |
| DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (NCT02156570) | Kirby Institute | 2014-10-01 |
| SMV + SOF With/Without RBV for IFN-II Patients With CHC (NCT02214420) | SC Liver Research Consortium, LLC | 2014-10-01 |
| Surveillance and Treatment of Prisoners With Hepatitis C (NCT02064049) | Kirby Institute | 2014-10-01 |
| Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) (NCT02203149) | Merck Sharp & Dohme LLC | 2014-08-01 |
| Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients (NCT02395198) | Prof. Dr. med. Jens Reimer | 2014-08-01 |
| A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin (NCT02474043) | University of Wisconsin, Madison | 2014-08-01 |
| Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (NCT02175966) | Bristol-Myers Squibb | 2014-07-28 |
| DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients (NCT02116179) | University of Delaware | 2014-07-01 |
| Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (NCT02098616) | Timothy Morgan, MD | 2014-07-01 |
| Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002) (NCT02161510) | Merck Sharp & Dohme LLC | 2014-07-01 |
| Control and Elimination Within Australia of Hepatitis C From People Living With HIV (NCT02102451) | Kirby Institute | 2014-07-01 |
| Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) (NCT02133131) | Merck Sharp & Dohme LLC | 2014-06-13 |
| Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy (NCT02877199) | Hospices Civils de Lyon | 2014-06-01 |
| Undiagnosed Hepatitis C Infection in an Urban Hospital (NCT01957085) | Temple University | 2014-06-01 |
| Prevalence of IL28B Polymorphism in Hepatitis C Patients (NCT03415009) | Changi General Hospital | 2014-06-01 |
| Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients (NCT01797848) | Bristol-Myers Squibb | 2014-06-01 |
| Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) (NCT03833362) | R-Pharm | 2014-05-07 |
| A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. (NCT02150291) | British University In Egypt | 2014-05-01 |
| TD-6450 MAD Study in HCV Infected Subjects (NCT02116543) | Theravance Biopharma | 2014-05-01 |
| Telaprevir in Genotype 3 HCV (NCT02087111) | Queen Mary University of London | 2014-04-01 |
| Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection (NCT02070107) | University of Louisville | 2014-04-01 |
| Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin (NCT02104843) | Bristol-Myers Squibb | 2014-04-01 |
| Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects (NCT02084953) | Bristol-Myers Squibb | 2014-04-01 |
| To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet (NCT02108639) | Bristol-Myers Squibb | 2014-04-01 |
| Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy (NCT02215525) | Egyptian Military Medical Services | 2014-04-01 |
| Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 (NCT02103569) | Bristol-Myers Squibb | 2014-04-01 |
| Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (NCT02095860) | Bristol-Myers Squibb | 2014-04-01 |
| Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients (NCT03057236) | University of North Carolina, Chapel Hill | 2014-03-01 |
| Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C (NCT02120274) | Federal University of São Paulo | 2014-03-01 |
| Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option (NCT02094443) | Debiopharm International SA | 2014-03-01 |
| Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant (NCT02032875) | Bristol-Myers Squibb | 2014-03-01 |
| Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (NCT01995266) | Bristol-Myers Squibb | 2014-02-28 |
| TD-6450 SAD and MAD in Healthy Subjects (NCT02022306) | Theravance Biopharma | 2014-02-01 |
| A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (NCT02032888) | Bristol-Myers Squibb | 2014-02-01 |
| Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects (NCT02045966) | Bristol-Myers Squibb | 2014-02-01 |
| Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA (NCT03318887) | Hospices Civils de Lyon | 2014-02-01 |
| Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing (NCT02068963) | Hologic, Inc. | 2014-02-01 |
| Ribavirin Bioavailability After Telaprevir Exposure (NCT02881034) | Hospices Civils de Lyon | 2014-02-01 |
| Drug Interaction & Methadone & Buprenorphine (NCT02045693) | Bristol-Myers Squibb | 2014-02-01 |
| Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (NCT02053519) | University of Dundee | 2014-02-01 |
| Patient-Centered Care and Asian Americans (NCT02139722) | University of California, San Francisco | 2014-01-02 |